Capecitabine is a chemotherapy drug used for breast and colorectal cancer. It can extend survival rate by nearly 10%. However, recent studies revealed that almost 50% of patients develop palmar-plantar erythrodysesthesia, ...
Sep 21, 2020
0
2
As many as one in 100 patients admitted to hospital with COVID-19 develop a pneumothorax—a 'punctured lung' - according to a study led by Cambridge researchers.
Sep 9, 2020
0
24
Dilated cardiomyopathy (DCM) is a leading cause of heart failure, affecting 1 in 250 people. DCM is characterized by an increase in the left ventricle of the heart, the main pumping chamber. The stretched heart muscle is ...
Sep 9, 2020
0
15
Dilated cardiomyopathy (DCM) is a leading cause of heart failure, affecting 1 in 250 people. The disease is characterized by an increase in size of the left ventricle of the heart. The stretched heart muscle is then unable ...
Sep 8, 2020
0
102
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in ...
Aug 18, 2020
0
1
Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients ...
Aug 8, 2020
0
2
(HealthDay)—For patients with diffuse large B-cell lymphoma (DLBCL), the combination of low muscle mass (LMM) and low muscle density (LMD) is an independent prognostic factor for survival, according to a study published ...
Jul 28, 2020
0
1
Pancreatic cancer carries a poor prognosis, and it often goes undetected until advanced stages. A new BJS (British Journal of Surgery) study indicates that a certain cocktail of chemotherapy drugs may be a safe and effective ...
Jul 8, 2020
0
2
Yale clinicians report promising results after treating COVID-19 patients at Yale New Haven Hospital (YNHH) with a drug that reduces hyperinflammation in cancer patients undergoing immunotherapy.
Jun 19, 2020
0
56
(HealthDay)—Lung cancer patients who are given the opportunity to be informed of their diagnosis have a longer median survival time, according to a study published in the May issue of Psycho-Oncology.
May 27, 2020
0
2
